<p>Sarepta Therapeutics（纳斯达克代码：SRPT - 获取免费报告）在周一向投资者发布的报告中，投资分析师将其目标价格从 28.00 美元下调至 20.00 美元，Benzinga 报道。该券商目前对这家生物技术公司的股票给予 “增持” 评级。摩根大通的目标价格意味着该股票相较于前一交易日收盘价有 42.15% 的潜在上涨空间。</p>
<p>获取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
<ul>
<li>Sarepta 因死亡事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
<p>SRPT 曾受到多份研究报告的关注。HC Wainwright 在 6 月 25 日的研究报告中重申了对 Sarepta Therapeutics 股票的 “卖出” 评级。Robert W. Baird 在周四的研究报告中将 Sarepta Therapeutics 的目标价格从 30.00 美元上调至 35.00 美元，并给予该股票 “跑赢大盘” 评级。Cantor Fitzgerald 在 6 月 16 日的研究报告中重申了对 Sarepta Therapeutics 股票的 “中性” 评级。加拿大皇家银行在周四的研究报告中将 Sarepta Therapeutics 的目标价格从 25.00 美元下调至 23.00 美元，并对该公司设定了 “行业表现” 评级。最后，瑞穗证券在 6 月 18 日的研究报告中将 Sarepta Therapeutics 的目标价格从 85.00 美元下调至 40.00 美元，并对该公司设定了 “跑赢大盘” 评级。一位研究分析师对该股票给予了 “卖出” 评级，十四位分析师给予 “持有” 评级，十一位分析师给予 “买入” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 55.33 美元。</p>
<p><strong>查看我们对 SRPT 的最新分析</strong></p>
<h2>Sarepta Therapeutics 股票下跌 36.0%</h2>
<ul>
<li>制药行业抛售：3 只 RSI 显示你不应忽视的股票</li>
</ul>
<p>纳斯达克 SRPT 周一开盘价为 14.07 美元。该公司的债务与股本比率为 1.00，流动比率为 4.02，速动比率为 2.46。该股票的市值为 13.8 亿美元，市盈率为-5.23，贝塔值为 0.45。Sarepta Therapeutics 的 1 年最低价为 11.95 美元，1 年最高价为 150.48 美元。该公司的 50 日移动平均线为 28.42 美元，200 日移动平均线为 67.58 美元。</p>
<p>Sarepta Therapeutics（纳斯达克代码：SRPT - 获取免费报告）最近于 5 月 6 日发布了其财报。这家生物技术公司报告本季度每股收益（EPS）为-3.42 美元，低于市场共识预期的 2.20 美元，差距为 5.62 美元。Sarepta Therapeutics 的净利润率为-11.12%，股本回报率为-14.88%。该季度的营业收入为 7.4486 亿美元，而分析师预期为 6.8575 亿美元。在去年同期，该公司的每股收益为 0.73 美元。Sarepta Therapeutics 本季度的收入同比增长 80.2%。卖方分析师预测，Sarepta Therapeutics 在当前年度的每股收益将达到 2.67 美元。</p>
<h2>机构投资者对 Sarepta Therapeutics 的看法</h2>
<ul>
<li>Solid Biosciences 能否在 DMD 市场挑战 Sarepta？</li>
</ul>
<p>一些大型投资者最近调整了对该公司的持股。Byrne Asset Management LLC 在第一季度新购入 Sarepta Therapeutics 的股份，价值 30,000 美元。Center for Financial Planning Inc.在第一季度新购入 Sarepta Therapeutics 的股份，价值 31,000 美元。Logan Capital Management Inc.在第四季度新购入 Sarepta Therapeutics 的股份，价值 61,000 美元。Ancora Advisors LLC 在第一季度将其在 Sarepta Therapeutics 的持股增加了 150.0%。Ancora Advisors LLC 目前拥有 500 股该生物技术公司的股票，价值 32,000 美元，此前在上个季度又购买了 300 股。最后，Hurley Capital LLC 在第四季度新购入 Sarepta Therapeutics 的股份，价值 76,000 美元。86.68% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Sarepta Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Sarepta Therapeutics, Inc.是一家商业阶段的生物制药公司，专注于 RNA 靶向治疗、基因疗法和其他基因治疗方式的发现与开发，旨在治疗罕见疾病。它提供 EXONDYS 51 注射剂，用于治疗具有可进行外显子 51 跳跃的肌营养不良症（Duchenne）的患者；VYONDYS 53 用于治疗具有可进行外显子 53 跳跃的肌营养不良症患者；AMONDYS 45 用于治疗具有确认的肌营养不良症基因突变的患者；以及 ELEVIDYS，一种基于腺病毒相关病毒的基因疗法，用于治疗 4 至 5 岁有确认肌营养不良症基因突变的步态儿童。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Sarepta Therapeutics</li>
<li>3 只超市股票证明它们仍然不可或缺</li>
<li>Iron Mountain 从其 1 年高点下跌 23%——是否被低估？</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>3 只 ETF 在一项重大美好法案推出时值得购买</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>随着比特币创下新高，这 3 只股票可能会爆炸</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Sarepta Therapeutics 吗？</h2>
<p>在考虑 Sarepta Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sarepta Therapeutics 并不在名单上。</p>
<p>虽然 Sarepta Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Sarepta医疗

<p>摩根大通已将 Sarepta Therapeutics（NASDAQ:SRPT）的目标股价从 28.00 美元下调至 20.00 美元，同时维持 “增持” 评级。这个新目标暗示该股票相较于前一交易日收盘价有 42.15% 的潜在上涨空间。其他分析师的观点各异，评级从卖出到跑赢大盘不等。Sarepta 的股票开盘价为 14.07 美元，市值为 13.8 亿美元，市盈率为-5.23。尽管每股收益出现亏损，该公司仍报告了同比 80.2% 的显著收入增长</p>

<p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price cut by investment analysts at JPMorgan Chase &amp; Co. from $28.00 to $20.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the biotechnology company's stock. JPMorgan Chase &amp; Co.'s target price would indicate a potential upside of 42.15% from the stock's previous close.</p>
<div class="lb-trans"><p>Sarepta Therapeutics（纳斯达克代码：SRPT - 获取免费报告）在周一向投资者发布的报告中，投资分析师将其目标价格从 28.00 美元下调至 20.00 美元，Benzinga 报道。该券商目前对这家生物技术公司的股票给予 “增持” 评级。摩根大通的目标价格意味着该股票相较于前一交易日收盘价有 42.15% 的潜在上涨空间。</p>
</div><p>Get <strong>Sarepta Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sarepta Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 因死亡事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
</div><p>SRPT has been the subject of a number of other research reports. HC Wainwright reaffirmed a &#34;sell&#34; rating on shares of Sarepta Therapeutics in a research report on Wednesday, June 25th. Robert W. Baird lifted their target price on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday. Cantor Fitzgerald reaffirmed a &#34;neutral&#34; rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Royal Bank Of Canada cut their price objective on shares of Sarepta Therapeutics from $25.00 to $23.00 and set a &#34;sector perform&#34; rating for the company in a research report on Thursday. Finally, Mizuho cut their price objective on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday, June 18th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $55.33.</p>
<div class="lb-trans"><p>SRPT 曾受到多份研究报告的关注。HC Wainwright 在 6 月 25 日的研究报告中重申了对 Sarepta Therapeutics 股票的 “卖出” 评级。Robert W. Baird 在周四的研究报告中将 Sarepta Therapeutics 的目标价格从 30.00 美元上调至 35.00 美元，并给予该股票 “跑赢大盘” 评级。Cantor Fitzgerald 在 6 月 16 日的研究报告中重申了对 Sarepta Therapeutics 股票的 “中性” 评级。加拿大皇家银行在周四的研究报告中将 Sarepta Therapeutics 的目标价格从 25.00 美元下调至 23.00 美元，并对该公司设定了 “行业表现” 评级。最后，瑞穗证券在 6 月 18 日的研究报告中将 Sarepta Therapeutics 的目标价格从 85.00 美元下调至 40.00 美元，并对该公司设定了 “跑赢大盘” 评级。一位研究分析师对该股票给予了 “卖出” 评级，十四位分析师给予 “持有” 评级，十一位分析师给予 “买入” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价格为 55.33 美元。</p>
</div><p><strong>View Our Latest Analysis on SRPT</strong></p>
<div class="lb-trans"><p><strong>查看我们对 SRPT 的最新分析</strong></p>
</div><h2>Sarepta Therapeutics Stock Down 36.0%</h2>
<div class="lb-trans"><h2>Sarepta Therapeutics 股票下跌 36.0%</h2>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>制药行业抛售：3 只 RSI 显示你不应忽视的股票</li>
</ul>
</div><p>NASDAQ SRPT opened at $14.07 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The stock has a market capitalization of $1.38 billion, a PE ratio of -5.23 and a beta of 0.45. Sarepta Therapeutics has a 1 year low of $11.95 and a 1 year high of $150.48. The business's 50-day moving average is $28.42 and its 200 day moving average is $67.58.</p>
<div class="lb-trans"><p>纳斯达克 SRPT 周一开盘价为 14.07 美元。该公司的债务与股本比率为 1.00，流动比率为 4.02，速动比率为 2.46。该股票的市值为 13.8 亿美元，市盈率为-5.23，贝塔值为 0.45。Sarepta Therapeutics 的 1 年最低价为 11.95 美元，1 年最高价为 150.48 美元。该公司的 50 日移动平均线为 28.42 美元，200 日移动平均线为 67.58 美元。</p>
</div><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.</p>
<div class="lb-trans"><p>Sarepta Therapeutics（纳斯达克代码：SRPT - 获取免费报告）最近于 5 月 6 日发布了其财报。这家生物技术公司报告本季度每股收益（EPS）为-3.42 美元，低于市场共识预期的 2.20 美元，差距为 5.62 美元。Sarepta Therapeutics 的净利润率为-11.12%，股本回报率为-14.88%。该季度的营业收入为 7.4486 亿美元，而分析师预期为 6.8575 亿美元。在去年同期，该公司的每股收益为 0.73 美元。Sarepta Therapeutics 本季度的收入同比增长 80.2%。卖方分析师预测，Sarepta Therapeutics 在当前年度的每股收益将达到 2.67 美元。</p>
</div><h2>Institutional Investors Weigh In On Sarepta Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Sarepta Therapeutics 的看法</h2>
</div><ul>
<li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li>
</ul>
<div class="lb-trans"><ul>
<li>Solid Biosciences 能否在 DMD 市场挑战 Sarepta？</li>
</ul>
</div><p>A number of large investors have recently modified their holdings of the company. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $30,000. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $31,000. Logan Capital Management Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $61,000. Ancora Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after buying an additional 300 shares in the last quarter. Finally, Hurley Capital LLC acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $76,000. 86.68% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对该公司的持股。Byrne Asset Management LLC 在第一季度新购入 Sarepta Therapeutics 的股份，价值 30,000 美元。Center for Financial Planning Inc.在第一季度新购入 Sarepta Therapeutics 的股份，价值 31,000 美元。Logan Capital Management Inc.在第四季度新购入 Sarepta Therapeutics 的股份，价值 61,000 美元。Ancora Advisors LLC 在第一季度将其在 Sarepta Therapeutics 的持股增加了 150.0%。Ancora Advisors LLC 目前拥有 500 股该生物技术公司的股票，价值 32,000 美元，此前在上个季度又购买了 300 股。最后，Hurley Capital LLC 在第四季度新购入 Sarepta Therapeutics 的股份，价值 76,000 美元。86.68% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Sarepta Therapeutics</h2>
<div class="lb-trans"><h2>关于 Sarepta Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc.是一家商业阶段的生物制药公司，专注于 RNA 靶向治疗、基因疗法和其他基因治疗方式的发现与开发，旨在治疗罕见疾病。它提供 EXONDYS 51 注射剂，用于治疗具有可进行外显子 51 跳跃的肌营养不良症（Duchenne）的患者；VYONDYS 53 用于治疗具有可进行外显子 53 跳跃的肌营养不良症患者；AMONDYS 45 用于治疗具有确认的肌营养不良症基因突变的患者；以及 ELEVIDYS，一种基于腺病毒相关病毒的基因疗法，用于治疗 4 至 5 岁有确认肌营养不良症基因突变的步态儿童。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Sarepta Therapeutics</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Iron Mountain Down 23% From Its 1-Year High—Is It Undervalued?</li>
<li>3 Stocks to Consider Buying in October</li>
<li>3 ETFs to Buy as the One Big Beautiful Bill Rolls Out</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>As Bitcoin Hits New Highs, These 3 Stocks Could Explode</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Sarepta Therapeutics</li>
<li>3 只超市股票证明它们仍然不可或缺</li>
<li>Iron Mountain 从其 1 年高点下跌 23%——是否被低估？</li>
<li>10 月值得考虑购买的 3 只股票</li>
<li>3 只 ETF 在一项重大美好法案推出时值得购买</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>随着比特币创下新高，这 3 只股票可能会爆炸</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=SRPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Sarepta Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sarepta Therapeutics 吗？</h2>
</div><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sarepta Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sarepta Therapeutics 并不在名单上。</p>
</div><p>While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sarepta Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

摩根大通给予 Sarepta Therapeutics（纳斯达克股票代码：SRPT）新的目标价为 20.00 美元